Pfizer: Morgan Stanley Downgrades to Equal-Weight, PT Cut to $32.
PorAinvest
viernes, 10 de octubre de 2025, 1:46 pm ET1 min de lectura
MS--
The downgrade follows a period of positive market sentiment, driven by the company's strategic agreements with the Trump administration, including a three-year reprieve on drug-import tariffs and a significant agreement with TrumpRx. These deals have bolstered Pfizer's outlook and attracted new investors, as evidenced by recent institutional holdings data [3].
However, Morgan Stanley's decision to cut its price target by $1.00 suggests a more cautious view of Pfizer's prospects. The firm's analysts cited increasing competitive pressures in specialty areas, particularly for Prevnar and Vyndamax, as a key factor behind the downgrade. They also noted that the company's earnings gap, partly due to an IPR&D charge related to its 3SBio partnership, is not fully reflected in other analysts' estimates [1].
Despite these concerns, Guggenheim has maintained its Buy rating and $33.00 price target on Pfizer, highlighting the company's strong fundamentals and attractive dividend yield of 6.8% [1]. The research firm forecasts Q3 2025 revenues at approximately $15.7 billion, with earnings per share projected at $0.58, slightly below consensus expectations.
Pfizer's upcoming Q3 earnings report on November 4, 2025, will be a crucial event for investors. The report is expected to provide insights into the company's progress in oncology and the impact of the tariff decision. Additionally, the company's agreement with TrumpRx, which includes offering drug discounts and committing $70 billion to U.S. manufacturing and R&D, is likely to attract new investors as the company meets its guidance.
Overall, while the market remains interested in Pfizer's potential for growth, the recent developments and strategic agreements will continue to shape the company's stock performance. Investors should closely monitor the upcoming earnings report and other key developments for further insights into Pfizer's prospects.
PFE--
Pfizer: Morgan Stanley Downgrades to Equal-Weight, PT Cut to $32.
On September 12, 2025, Morgan Stanley downgraded Pfizer Inc. (NYSE:PFE) to an "Equal-Weight" rating, reducing its price target from $33.00 to $32.00. This move comes amidst a mixed bag of recent developments for the pharmaceutical giant.The downgrade follows a period of positive market sentiment, driven by the company's strategic agreements with the Trump administration, including a three-year reprieve on drug-import tariffs and a significant agreement with TrumpRx. These deals have bolstered Pfizer's outlook and attracted new investors, as evidenced by recent institutional holdings data [3].
However, Morgan Stanley's decision to cut its price target by $1.00 suggests a more cautious view of Pfizer's prospects. The firm's analysts cited increasing competitive pressures in specialty areas, particularly for Prevnar and Vyndamax, as a key factor behind the downgrade. They also noted that the company's earnings gap, partly due to an IPR&D charge related to its 3SBio partnership, is not fully reflected in other analysts' estimates [1].
Despite these concerns, Guggenheim has maintained its Buy rating and $33.00 price target on Pfizer, highlighting the company's strong fundamentals and attractive dividend yield of 6.8% [1]. The research firm forecasts Q3 2025 revenues at approximately $15.7 billion, with earnings per share projected at $0.58, slightly below consensus expectations.
Pfizer's upcoming Q3 earnings report on November 4, 2025, will be a crucial event for investors. The report is expected to provide insights into the company's progress in oncology and the impact of the tariff decision. Additionally, the company's agreement with TrumpRx, which includes offering drug discounts and committing $70 billion to U.S. manufacturing and R&D, is likely to attract new investors as the company meets its guidance.
Overall, while the market remains interested in Pfizer's potential for growth, the recent developments and strategic agreements will continue to shape the company's stock performance. Investors should closely monitor the upcoming earnings report and other key developments for further insights into Pfizer's prospects.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios